Newsletters

  • All
  • AMR Action Fund
  • Can you help?
  • CARB-X
  • CDC
  • FDA
  • Government Action
  • Jobs
  • Meetings
  • PK & PK-PD
  • Push/Pull
  • R&D Insight
  • RFPs
  • Something Different
  • Summaries
  • Wellcome Trust
  • WHO
  • Wonkish
All
  • All
  • AMR Action Fund
  • Can you help?
  • CARB-X
  • CDC
  • FDA
  • Government Action
  • Jobs
  • Meetings
  • PK & PK-PD
  • Push/Pull
  • R&D Insight
  • RFPs
  • Something Different
  • Summaries
  • Wellcome Trust
  • WHO
  • Wonkish
R&D InsightWonkish

DTR Gram-negative infections: Are new antibiotics making a difference?

Dear All (and with thanks to Aaron Dane for co-authoring this newsletter AND inhale, exhale … this is going to be ...
Read More >
R&D Insight

AMR Science-Policy Symposia (ESCMID 2026): Smart policies for lean times

Dear All: ESCMID Global once again held an afternoon of sessions focused on the intersection of AMR-related science and policy. ...
Read More >
R&D Insight

Wellcome Leap: $50m for gut-sparing approaches to antibiotic delivery

Dear All: I’ve just learned of a funding call from Wellcome Leap entitled “Focused antibiotics.” The thesis of the call ...
Read More >
R&D InsightWonkish

Anti-Gram-negative beta-lactams in jeopardy: The rise of PBP3 mutations

Dear All (and with thanks to Robert Bonomo and Patricia Bradford for guiding me on this newsletter; anything that’s correct ...
Read More >
R&D Insight

AMR Surveillance Data Challenge – Vivli 2026 Call for Projects!

Dear All, I’ve written before about the Vivli data challenge (2024 edition, 2025 edition) and am pleased to be able ...
Read More >
R&D Insight

GO-Dx: Global One Health Diagnostics Access Compact

Dear All, Building on the concepts of the January 2016 Industry-led Davos Declaration on action on AMR (website;.pdf declaration; yes, ...
Read More >
R&D InsightSomething Different

The language of AMR: The power of metaphor

Dear All, Acronyms and jargon fill our daily scientific lives but can be impenetrable to newcomers. A great example is ...
Read More >
R&D Insight

Great AMR-focused podcast series on BBC Discovery!

Dear All, The BBC’s Roland Pease has put together a 3-part podcast series on AMR! Each episode is about 30 ...
Read More >
R&D Insight

Antimicrobial Effectiveness: The strategic economic value of antibiotics

Dear All (and with thanks to Lucy Naga for being the lead author on this economic-focused newsletter), Antimicrobials are the ...
Read More >
R&D Insight

WHO: New TPPs for antibacterial agents

Dear All, You may recall that in 2019-2020, WHO developed a set of TPPs (TPP = Target Product Profile = A ...
Read More >
Government ActionR&D Insight

EMA: “Regulatory sandboxes” to explore approval pathways

Dear All, No, EMA has not decided to set up shop on the beach! Rather, the point of this newsletter is ...
Read More >
R&D Insight

CARB-X seeks new Chief of R&D (fully remote, worldwide)

Dear All, A very senior and globally significant leadership opportunity has appeared: CARB-X is seeking to recruit a new Chief of Research ...
Read More >
FDAR&D Insight

FDA: One pivotal trial (+ confirmatory evidence) is default expectation for approval

Dear All (a wonkish guide to something you may have thought was obvious AND with thanks to Aaron Dane for ...
Read More >
R&D Insight

Workshop on diagnostics: Can we drive use by making value visible?

Dear All (and with thanks to Robert Skov for co-authoring this newsletter AND with a wonkish alert for this complicated ...
Read More >
Government ActionPush/Pull

PASTEUR (v2.0) reintroduced in the US Congress!

Dear All, I’m delighted to be able to say that PASTEUR 2026 was (re)introduced into the US Congress this week! ...
Read More >
R&D Insight

The global funding pipeline, 2017-2023: A review

Dear All, In a thoughtful companion to WHO’s preclinical and clinical pipeline reviews, we now have an instructive analysis of ...
Read More >
R&D Insight

FDA RFPs: Susceptibility breakpoints and external controls for invasive fungal infections

Dear All, I just today learned that FDA has posted two antimicrobial resistance-related (AMR-related) FY 2026 funding opportunities. The titles ...
Read More >
R&D InsightWonkish

Two new oral drugs for gonorrhea!

Dear All (wonkish … but worth it … get ready to follow the links!), Greetings in the new year! As ...
Read More >
R&D Insight

CARB-X Novel Chemistry for AMR Challenge

Dear All, Happy New Year! As a great start for January, Team CARB-X have announced (i) that they will have two ...
Read More >
R&D InsightSomething Different

The threat of mirror bacteria: Ongoing conversations (2025 wrap-up)

Dear All, Regular readers will be aware of the global conversation now happening around the threat arising from the potential ...
Read More >
Scroll to Top